Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

202 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Physical recovery across care pathways up to 12 months after hospitalization for COVID-19: A multicenter prospective cohort study (CO-FLOW).
Berentschot JC, Heijenbrok-Kal MH, Bek LM, Huijts SM, van Bommel J, van Genderen ME, Aerts JGJV, Ribbers GM, Hellemons ME, van den Berg-Emons RJG; CO-FLOW Collaboration Group. Berentschot JC, et al. Among authors: aerts jgjv. Lancet Reg Health Eur. 2022 Aug 24;22:100485. doi: 10.1016/j.lanepe.2022.100485. eCollection 2022 Nov. Lancet Reg Health Eur. 2022. PMID: 36039177 Free PMC article.
OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum.
van der Sluis TC, Beyrend G, van der Gracht ETI, Abdelaal T, Jochems SP, Belderbos RA, Wesselink TH, van Duikeren S, van Haften FJ, Redeker A, Ouboter LF, Beyranvand Nejad E, Camps M, Franken KLMC, Linssen MM, Hohenstein P, de Miranda NFCC, Mei H, Bins AD, Haanen JBAG, Aerts JG, Ossendorp F, Arens R. van der Sluis TC, et al. Cell Rep Med. 2023 Mar 21;4(3):100939. doi: 10.1016/j.xcrm.2023.100939. Epub 2023 Feb 15. Cell Rep Med. 2023. PMID: 36796366 Free PMC article.
Long-term health outcomes of COVID-19 in ICU- and non-ICU-treated patients up to 2 years after hospitalization: a longitudinal cohort study (CO-FLOW).
Berentschot JC, Bek LM, Heijenbrok-Kal MH, van Bommel J, Ribbers GM, Aerts JGJV, Hellemons ME, van den Berg-Emons HJG; CO-FLOW collaboration Group. Berentschot JC, et al. Among authors: aerts jgjv. J Intensive Care. 2024 Nov 8;12(1):47. doi: 10.1186/s40560-024-00748-w. J Intensive Care. 2024. PMID: 39516956 Free PMC article.
Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.
van 't Land FR, Willemsen M, Bezemer K, van der Burg SH, van den Bosch TPP, Doukas M, Fellah A, Kolijn PM, Langerak AW, Moskie M, van der Oost E, Rozendaal NEM, Baart SJ, Aerts JGJV, van Eijck CHJ. van 't Land FR, et al. Among authors: aerts jgjv. J Clin Oncol. 2024 Sep 10;42(26):3083-3093. doi: 10.1200/JCO.23.02585. Epub 2024 Jul 1. J Clin Oncol. 2024. PMID: 38950309 Free PMC article. Clinical Trial.
Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.
Ernst SM, van Marion R, Atmodimedjo PN, de Jonge E, Mathijssen RHJ, Paats MS, de Bruijn P, Koolen SL, von der Thüsen JH, Aerts JGJV, van Schaik RHN, Dubbink HJ, Dingemans AC. Ernst SM, et al. Among authors: aerts jgjv. J Thorac Oncol. 2024 Jul;19(7):995-1006. doi: 10.1016/j.jtho.2024.04.007. Epub 2024 Apr 12. J Thorac Oncol. 2024. PMID: 38615940 Free article.
The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy.
Martin MV, Aguilar-Rosas S, Franke K, Pieterse M, Langelaar JV, Schreurs R, Bijlsma MF, Besselink MG, Koster J, Timens W, Khasraw M, Ashley DM, Keir ST, Ottensmeier CH, King EV, Verheij J, Waasdorp C, Valk PJM, Engels SAG, Oostenbach E, van Dinter JT, Hofman DA, Mok JY, van Esch WJE, Wilmink H, Monkhorst K, Verheul HMW, Poel D, Hiltermann TJN, Kempen LCLTV, Groen HJM, Aerts JGJV, Heesch SV, Löwenberg B, Plasterk R, Kloosterman WP. Martin MV, et al. Among authors: aerts jgjv. Cancer Immunol Res. 2024 Jun 4;12(6):759-778. doi: 10.1158/2326-6066.CIR-23-0158. Cancer Immunol Res. 2024. PMID: 38573707
202 results